A Digital Platform Empowering Patients and Accelerating Therapy Development for Inherited Neuromuscular Disorders
Our Benefits
Genetic neuromuscular disorders accompany patients throughout their entire lives. gaitMATE, as a digital platform, sits at the interface of patient guidance, specialist care, and drug development.
- For patients: Get access to individualized recommendations tailored to your current needs, find a specialist, and easily export all relevant information to prepare for your visit.
- For clinicians: Receive concise overviews of patient histories, monitor disease progression and therapy effects remotely, and save time during visits.
- For research and drug development: Reach more patients suitable for your clinical studies, and remotely collect high-quality data in a safe and patient-centered manner for your research.
An advanced approach to measuring disease state
Utilizing GaitMATE’s remote data capture tools, we’re developing a suite of cutting-edge digital clinical outcome assessments designed to transform patient care and research. Using video-based motion detection technology, specifically engineered for the common movement challenges and compensation patterns associated with genetic neuromuscular diseases, we innovate digital monitoring in neuromuscular disease. Together with our collaborators at Columbia University in New York and around the globe, we measure disease state, progression, and therapy response, closing feedback loops in clinical practice.
About us
- Dr. Helena Pernice, a neurologist at the Charité University Medical Center in Berlin, Germany, specializing in rare and genetic neuromuscular diseases. She is also a CMT patient and is involved in patient advocacy groups.
- Ass. Prof. Wolfgang Pernice, PhD, head of the Laboratory of Digital Biology, a researcher in genetics, digital biology, and AI at Columbia University in New York, USA.
- Paul Wetzel, a software developer at Technical University of Berlin, Germany.
- PD Dr. Katrin Hahn, neuromuscular specialist and head of the Neuromuscular Group and Amyloidosis Center (ACCB) at the Charité University Medical Center in Berlin, Germany.
Stakeholder Feedback for gaitMATE
What we are currently missing a lot in neurological trials is the interconnection between some quality of life parameters and clinical endpoints. […] This GaitMATE proposition is a very, very efficient benefit for patients and also for the German healthcare system!
Pharmaceutical executive
As we move into the age of therapeutic interventions for CMT, that’s where it will be useful. You can also say that if you are having a decline at this rate, a patient will be eligible for the trial!
Neurologist from the US
I think the value, in my opinion, is huge: being more patient-centric, having more real-related outcomes, and less workload in study sites. […] I think it’s a great idea. Walking is crucial; it’s extremely important!
Pharmaceutical executive
Gait in CMT is really important! It’s critical! Looking at the gait, looking at the muscle bulk, testing power…
UK Neurologist
